David Rudolf Current Role and Professional Background
David Rudolf is an American attorney and partner at the law firm Rudolf Law Firm PLLC, based in Charlotte, North Carolina. He is best known for representing high-profile clients in criminal defense, civil litigation, and regulatory matters. As of 2025, he serves as outside general counsel and board advisor to CytoDyn Inc., a clinical-stage biopharmaceutical company developing leronlimab for HIV and COVID-19 indications. He also maintains an active litigation practice focused on white-collar defense and complex commercial disputes according to recent company filings and coverage.
Key Career Milestones
Rudolf founded the Rudolf Law Firm after serving as a federal prosecutor and later as a partner at major national law firms. He has handled matters involving securities fraud, regulatory investigations, and internal corporate investigations. His representation of CytoDyn has included navigating SEC disclosures and public company governance issues as documented in SEC EDGAR filings. He is frequently cited in legal and financial media for his commentary on white-collar defense strategy.
David Rudolf Net Worth and Financial Profile
David Rudolf's estimated net worth in 2025 is in the range of several million dollars, derived from his law firm earnings, advisory roles, and equity positions in private and public companies. His compensation at CytoDyn includes cash retainers and stock-based awards tied to clinical and regulatory milestones. Public disclosures show he holds direct and indirect positions in CytoDyn equity, though the exact value fluctuates with share price and vesting schedules based on recent Forbes coverage.
Sources of Income and Holdings
His income streams include law firm billings, advisory fees from biopharmaceutical and technology clients, and potential gains from equity holdings. CytoDyn's market capitalization and leronlimab development progress directly affect the valuation of his equity stake. He has also been involved in ventures related to cannabis and regulatory compliance, which contribute to his overall financial profile per SEC filings.
David Rudolf Today: Latest Cases and Public Profile
In 2025, David Rudolf continues to represent clients in high-stakes litigation and regulatory matters. He remains a visible figure in legal and financial media, offering analysis on white-collar defense, corporate governance, and biopharmaceutical regulation. His current public focus includes advising CytoDyn on ongoing clinical programs and SEC compliance requirements as reported by Forbes.
Recent Public and Legal Activity
Rudolf has been involved in matters involving